General
Preferred name
MK-0249
Synonyms
MK-0249 FA(862309-06-6 Free base) ()
MK 0249 ()
MK0249 ()
MK-0249 FA ()
P&D ID
PD047129
CAS
1167574-41-5
862309-06-6
Tags
available
drug candidate
Drug indication
Attention deficit hyperactivity disorder
Insulin-resistant disorder
Drug Status
investigational
Max Phase
2.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
H3 receptor inverse agonists may be efficacious for central nervous system disorders, including excessive daytime sleepiness, attention deficit hyperactivity disorder, Alzheimer disease, ethanol addiction, and obesity .
(GtoPdb)
DESCRIPTION
MK-0249 (Compound 1) is a potent, selective and orally active histamine H3 receptor antagonist, with an IC50 of 1.7 nM for human H3[1].
PRICE
784
PRICE
1066
DESCRIPTION
This active molecular is a potent histamine H3 inverse antagonist. Current antipsychotic treatments have little impact on the cognitive deficits associated with schizophrenia. MK-0249 might improve cognitive deficits in patients with schizophrenia in due to promote histamine release that may enhance cognition. In Dec 2006, Phase-II clinical trials in Alzheimer's disease in USA was on going. In Dec 2009, adverse events data from a clinical trial in healthy subjects was presented. In Jun 2012, Pharmacodynamics data from a phase I trial in Sleep apnoea syndrome was reported by Merck.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
MK-0249 is an orally active, selective and potent histamine H3 receptor antagonist (IC50: 1.7 nM) for the study of attention-deficit and hyperactivity disorders.
(TargetMol Bioactive Compound Library)
DESCRIPTION
MK-0249 FA is an orally active, selective and potent histamine H3 inverse agonist for the study of attention deficit, hyperactivity disorder neurodivergent and cognitive disorders in adults.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
13
BOC Sciences Bioactive Compounds
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
DrugBank
DrugMAP
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
ReFrame library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
22
Molecular Weight
431.18
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
0
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
3
cLogP
4.58
TPSA
47.36
Fraction CSP3
0.39
Chiral centers
0.0
Largest ring
6.0
QED
0.54
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Immunology/Inflammation
Neuroscience
Neuronal Signaling
Target
Histamine Receptor
H3 receptor (human)
H3 receptor
Solubility
Soluble in DMSO
Source data
